Top

Published in:

01-09-2021 | Kidney Cancer | Letter to the Editor

Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept

Authors: Zine‐Eddine Khene, Romain Mathieu, Benoit Peyronnet, Romain Kokorian, Anis Gasmi, Fares Khene, Nathalie Rioux-Leclercq, Solène-Florence Kammerer-Jacquet, Shahrokh Shariat, Brigitte Laguerre, Karim Bensalah

Published in: World Journal of Urology | Issue 9/2021

Excerpt

Dear Editor, …

Available only for authorised users

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665CrossRefPubMedPubMedCentral

Dudani S, Savard M-F, Heng DYC (2020) An update on predictive biomarkers in metastatic renal cell carcinoma. Eur Urol Focus 6:34–36. https://doi.org/10.1016/j.euf.2019.04.004CrossRefPubMed

Azuaje F (2019) Artificial intelligence for precision oncology: beyond patient stratification. NPJ Precis Oncol. https://doi.org/10.1038/s41698-019-0078-1CrossRefPubMedPubMedCentral

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures. They Are Data Radiol 278:563–577. https://doi.org/10.1148/radiol.2015151169CrossRef

Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. https://doi.org/10.1038/ncomms5006CrossRefPubMedPubMedCentral

Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am J Roentgenol 195:281–289. https://doi.org/10.2214/AJR.09.4110CrossRef

Alessandrino F, Gujrathi R, Nassar AH, Alzaghal A, Ravi A, McGregor B et al (2019) Predictive role of computed tomography texture analysis in patients with metastatic urothelial cancer treated with programmed death-1 and programmed death-ligand 1 inhibitors. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.02.002CrossRefPubMed

Hectors SJ, Cherny M, Yadav KK, Beksaç AT, Thulasidass H, Lewis S et al (2019) Radiomics Features Measured With Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness. J Urol 202:498–505. https://doi.org/10.1097/JU.0000000000000272CrossRefPubMed

Roviello G, Corona SP, Nesi G, Mini E (2019) Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? Ther Adv Med Oncol 11:175883591986190. https://doi.org/10.1177/1758835919861905CrossRef

Title: Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept
Authors: Zine‐Eddine Khene
Romain Mathieu
Benoit Peyronnet
Romain Kokorian
Anis Gasmi
Fares Khene
Nathalie Rioux-Leclercq
Solène-Florence Kammerer-Jacquet
Shahrokh Shariat
Brigitte Laguerre
Karim Bensalah
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Kidney Cancer
Artificial Intelligence
Kidney Cancer
Published in: World Journal of Urology / Issue 9/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03334-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2021

Artificial urinary sphincter implantation in non-neurogenic men: a place for out-patient surgery

Comment on “Bipolar versus monopolar transurethral resection of non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials”

Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes

Scoping review: hotspots for COVID-19 urological research: what is being published and from where?

PHI density prospectively improves prostate cancer detection

Enhanced antibiotic prophylaxis and infection-related complications following prostate biopsy